Product nameFirePlex®-384 Cytokines (Human) Immunoassay Panel 1 (ab286832)
Sample typeCell culture supernatant, Serum, Plasma, Hep Plasma, EDTA Plasma, Cit plasma
Species reactivityReacts with: Human
FirePlex®-384 Cytokines (Human) Immunoassay Panel 1 (ab286832) uses FirePlex® particle technology to quantify IL-8, IFN gamma, IL-4, IL-1 beta, MCP1, TNF alpha, IL-10, IL-17A, IL-2, IL-6 from 6.25 µl of sample input in 384-well plate format.
Assays are validated in serum, plasma, and cell culture supernatant, and can be run with 175 samples in duplicate per 384-well plate.
The two-step workflow and no-wash assay format limit hands-on time and are amenable to automation, thus making FirePlex®-384 ideally suited for high-throughput screening studies. Assay readout is conducted on high-content imagers with data analysis using the FirePlex® Analysis Workbench software.
Users should note that assay performance data supplied in the accompanying Product Datasheet is a representative dataset, and is not lot-specific. For lot-specific assay performance data, please refer to the product's certificate of analysis, which can be found here.
FirePlex® is a registered trade mark in certain territories (including Europe and the United States) and is an unregistered trade mark elsewhere.
This kit has been used in the following paper, click here for the link.
A Multi-Phenotype System to Discover Therapies for Age-Related Dysregulation of the Immune Response to Viral Infections
This product is currently only supported for customers in North America and Europe, if you are outside these areas please contact us.
The following table provides the sensitivity, dynamic range, and CVs forFirePlex®-384 Cytokines (Human) Immunoassay Panel 1*.
IFN gamma 4.21 13.7 - 10,000 6.3% IL-1 beta 0.78 1.52 - 3,333 7.8% IL-2 3.76 4.57 - 10,000 8.8% IL-4 2.58 4.57 - 10,000 4.1% IL-6 1.33 4.57 - 10,000 15.8% IL-8 1.00 1.52 - 3,333 5.5% IL-10 3.62 457 - 10,000 8.9% IL-17A 2.41 4.57 - 10,000 7.6% MCP1 0.89 1.52 - 3,333 4.1% TNF alpha 25.78 41.15 - 10,000 8.9%
*representative dataset, not lot-specific. For lot-specific assay performance data, please refer to the product's certificate of analysis, which can be found here.
Storage instructionsPlease refer to protocols.
Components 1 x 384 tests 384 Well Imaging Plate 1 x 384 tests 384 Well Imaging Plate Lid 1 unit 384 Well Imaging Plate Seal 2 units FirePlex-384 - Imaging Dye Concentrate 1 x 875µl FirePlex-384 1X PBS 1 x 8ml FirePlex-384 35X Detector Antibody Mix 1 x 110µl FirePlex-384 5X Capture Particle Mix 1 x 700µl FirePlex-384 Human Protein Standard Mix HTA 1 x 7 tests FirePlex-384 Reagent Diluent R1 1 x 8ml FirePlex-384 Sample Diluent S1 1 x 25ml
Cellular localizationTNF alpha: Secreted and Cell membrane. IL-8: Secreted. MCP1: Secreted. IL-6: Secreted. IL-10: Secreted. Interferon gamma: Secreted. IL-1 beta: Cytoplasm, cytosol. Lysosome. Secreted, exosome. Cytoplasmic vesicle, autophagosome. Secreted. The precursor is cytosolic. In response to inflammasome-activating signals, such as ATP for NLRP3 inflammasome or bacterial flagellin for NLRC4 inflammasome, cleaved and secreted. IL1B lacks any known signal sequence and the pathway(s) of its secretion is(are) not yet fully understood (PubMed:24201029). On the basis of experimental results, several unconventional secretion mechanisms have been proposed. 1. Secretion via secretory lysosomes: a fraction of CASP1 and IL1B precursor may be incorporated, by a yet undefined mechanism, into secretory lysosomes that undergo Ca(2+)-dependent exocytosis with release of mature IL1B (PubMed:15192144). 2. Secretory autophagy: IL1B-containing autophagosomes may fuse with endosomes or multivesicular bodies (MVBs) and then merge with the plasma membrane releasing soluble IL1B or IL1B-containing exosomes (PubMed:24201029). However, autophagy impacts IL1B production at several levels and its role in secretion is still controversial. 3. Secretion via exosomes: ATP-activation of P2RX7 leads to the formation of MVBs containing exosomes with entrapped IL1B, CASP1 and other inflammasome components. These MVBs undergo exocytosis with the release of exosomes. The release of soluble IL1B occurs after the lysis of exosome membranes (By similarity). 4. Secretion by microvesicle shedding: activation of the ATP receptor P2RX7 may induce an immediate shedding of membrane-derived microvesicles containing IL1B and possibly inflammasome components. The cytokine is then released in the extracellular compartment after microvesicle lysis (PubMed:11728343). 5. Release by translocation through permeabilized plasma membrane. This may occur in cells undergoing pyroptosis due to sustained activation of the inflammasome (By similarity). These mechanisms may not be not mutually exclusive. IL-2: Secreted. IL-4: Secreted. IL-17A: Secreted.
ab286832 has not yet been referenced specifically in any publications.